TTUHSC Optometry Conference

Diabetes 2020

Kelly T. Mitchell, MD

Professor Retina Service Department of Ophthalmology Texas Tech University Health Sciences Center



Clearly communicate to each of you what I think is important for you to know about diabetic eye disease

What is Diabetic Eye Disease?

- 1. Is it premature cataracts?
- 2. Is it the premature presbyopia?
- 3. Is it a cause for double vision and or a droopy eyelid?
- 4. Can lead to a potentially fatal type of orbital infection?
- 5. Is it primarily a disease that effects the blood vessels of the retina?


YES!!!


Diabetic Eye Disease – Cataracts

- 1. Diabetic patients are twice as likely to develop visually significant cataracts.
- 2. These cataracts can occur earlier often in middle age (40's)
- 3. The surgery is the same as for nondiabetics, but depending on the retinal disease may also treat macular edema concurrently.
 - 1. They may have already been treated with intravitreal injections which can increase the risk of cataract surgery complications
 - 2. The cataract surgery may be planned to facilitate diabetic laser TX or may occur at the same time as PPV

Diabetic Eye Disease – Early Reading Glasses

- 1. Presbyopia is the term used to describe the need for reading glasses that depending on glasses prescription (refraction) occurs in 40s
- 2. In diabetics this can occur earlier.
- 3. WHY? Ischemic injury to ciliary muscle






Diabetic Eye Disease: Double vision & droopy lids


- 1. Diabetic patients can experience double vision (diplopia) and a droopy lid (ptosis)
- 2. WHY = CN 3 palsy
 - 1. Diabetic related = usually sparing the pupil
 - 2. Aneurysm related = usually pupil involved






Diabetic Eye Disease: Double vision & droopy lids












Diabetic Eye Disease: Orbital Mucormycosis











Diabetic Eye Disease: Orbital Mucormycosis


- 1. Diabetic patients, especially those in DKA can experience a severe form of orbital fungal infection
 - 1. Ocular Symptoms:
 - Ophthalmoplegia (poor or no eye movements), Proptosis, Visual Loss, Chemosis (swollen conjunctiva), Lid gangrene
 - 2. Non-ocular symptoms:
 - 1. Sinusitis, nasal discharge/ulceration, palatal necrosis
 - 3. Neuro symptoms:
 - 1. Cerebral lobe signs, hemiparsis
- 2. Emergent Systemic antifungals +/- surgery +/are only chance for survival

Diabetic Statistics


Prevalence rate: 10.5% or 34.3 million 26.9 million diagnosed (7.3 million undiagnosed) 18-44 2.6% 45-64 12.9% 65-74 25.2% 75+ 21.1%


Incidence rate: 0.7% or 1.5 million DX/yr (6.5% of the prevalence rate) 2030 the estimate is over 50 million diabetics in US


Number and Percentage of U.S. Population with Diagnosed Diabetes, 1958-2015



CDC's Division of Diabetes Translation. United States Diabetes Surveillance System available at http://www.cdc.gov/diabetes/data








Prediabetic/Borderline Diabetic 34.9% of adults 18+ 48.3% of adults 65+


The Diabetic Statistics of Texas






Texas **11.2%** Lubbock **8.9%**

Age-adjusted Prevalence of Obesity and Diagnosed Diabetes Among US Adults











*Sample size <50 or the relative standard error (dividing the standard error by the prevalence) \ge 30%.

[¶] Prevalence estimates reflect BRFSS methodological changes started in 2011. These estimates should not be compared to prevalence estimates before 2011.



*Sample size <50 or the relative standard error (dividing the standard error by the prevalence) \geq 30%.


¹ Prevalence estimates reflect BRFSS methodological changes started in 2011. These estimates should not be compared to prevalence estimates before 2011.



*Sample size <50 or the relative standard error (dividing the standard error by the prevalence) \geq 30%.




¹ Prevalence estimates reflect BRFSS methodological changes started in 2011. These estimates should not be compared to prevalence estimates before 2011.



*Sample size <50 or the relative standard error (dividing the standard error by the prevalence) \geq 30%.

Where Diabetes is Most Prevalent in the U.S.

Percent of adults who have ever been told by a doctor that they have diabetes (2017*)



* latest on record

@StatistaCharts Sources: Kaiser Family Foundation, CDC





Insert your desired text here.

Obese

Overweight

Healthy Weight

Underweight

Source: US Surgeon General - Chart is for Adults (aged 20 years and older)

Imperial English BMI Formula weight (lbs) x 703 + height (in²)

> Metric BMI Formula weight (kg) / height (m²)

Risk Factors for Complications

- 1. Smoking 16% // 35% (active//former)
- 2. Overweight 87.5% (BMI > 25)
- 3. Physical Inactivity 40.8% (self-reported)
- 4. High Blood Pressure
 - 74% (SBP>140 //DPB > 90)
- 5. High Cholesterol 58% // 67% (-CVD + statin // +CVD + statin)
- 6. High Blood Glucose
 - 16% (A1c >9%)

Diabetic Disease Load

- **1.Death rate:**
 - #7 (2x non-DM)
- 2. Morbidities:
 - Heart Disease (2x)
 - Stroke (2x)
 - Kidney Failure (HTN and DM)
 - Extremity numbness and amputations
 - **Sexual Dysfunction**
 - Pregnancy Challenges
 - Vision loss/blindness (#1 in adults 20-70ys)

Diabetic Retinopathy (DR) Statistics

Overall DR Prevalence 30% 30% are undiagnosed 5% have vision-threatening DR (VTDR)

Less than 60% of patients get yearly eye exams

Natural History of DR Good data from clinical research Natural Course DR moves orderly from mild to severe stages Treatment Options and Outcomes 80% effective at preventing severe vision OSS Less predictable at restoring vision after vision loss has occurred

Natural History I

- 1. Impact of Type of DM and Duration
- 2. Type 1
 - < 5 yrs: Basically no disease
 - > 5 yrs: 25% have DR
 - >10 yrs: 60% have DR
 - >15 yrs: 80% have DR
 - >20 yrs: 95% have DR and 50% have VTDR

Natural History II

- 1. Impact of Type 2 DM and Duration
- 2. Type 2
 - < 5 years

20% have DR at diagnosis (-insulin)40% have DR at diagnosis (+insulin)2% have VTDR at diagnosis

> 20 years
60% any DR,
30% VTDR

DR Care Process: Evaluation

Recommended Eye Exam for DR

Type I DM Initial Exam Follow-up

Type 2 DM Initial Exam Follow-up

Pregnancy Initial Exam Follow-up 5 years after Diagnosis Yearly with no DR Sooner based on DR severity

At Diagnosis Yearly Sooner Based on DR severity

1st trimester No DR at end of pregnancy + DR Q3 months or sooner

DR Severity Scale I

No DR = no abnormalities seen

Mild NonProliferative NPDR = microaneurysms (MAs)


Moderate NPDR = > MAs but < Severe NPDR

Severe NPDR = "4-2-1 Rule" & no proliferative Δs 4 quadrants of severe hemorrhages 2 quadrants of venous beading 1 quadrants of IRMA IntraRetinal Microvascular Abnormality

DR Severity Scale II VTDR Proliferative Diabetic Retinopathy PDR one or both: Neovascularization Vitreous/preretinal Bleeding **Diabetic macular Edema DME** absent present mild = distant from center macula moderate = closer to center macula severe = involving center of macula DR related tractional Retinal Detachment TRD

Retinopathy Exam Direct ophthalmoscopy (-/+ dilation) "a long run for a short slide" (blasphemy for a retina surgeon)








Important exceptions: Pediatric Red Reflex




Optic Nerve Evaluation






Mild Non Proliferative Diabetic Retinopathy (NPDR)




Moderate Non Proliferative Diabetic Retinopathy NPDR




Severe Non Proliferative Diabetic Retinopathy NPDR



Proliferative Diabetic Retinopathy (PDR)
























OCTA of Diabetic Retinopathy: Impaired Perfusion













Diabetic Macular Edema










Optical Coherence Tomography



Proliferative Diabetic Retinopathy PDR with traction retinal detachment TRD







DR Care Process: Systemic Risks

Blood Sugar Blood sugar Levels:

| Fasting blood | glucose |
|-------------------------------|---------------------|
| Normal | less than 100 mg/dL |
| High risk | 100-125 mg/dL |
| Diabetes | 126 mg/dL or higher |
| Hemodehin / | Me. |
| Hemoglobin / | 1 |
| Normal | less than 5.7% |
| | |

A1-C levels: measures glycosylated protein n RBCs which gives a 2-3 month average of BS 28.7 X A1C – 46.7 = eAG (estimated Average Glucose) Better control reduces onset and slows progression of DR (DCCT): delayed start of DR by 76% delayed progression by 54% delayed nephropathy by 40%

DR Care Process: Systemic Risks

Blood Pressure

In Diabetic Patients American Diabetes Association (ADA) defines hypertension as SBP ≥140 mmHg and DBP ≥90 mmHg that is confirmed during separate clinic visits

In nondiabetic Patients Normal: Less than 120/80 mm Hg: Elevated: Systolic between 120-129 and diastolic less than 80; Stage 1: Systolic between 130-139 or diastolic between 80-89; Stage 2: Systolic at least 140 or diastolic at least 90 mm Hg; Hypertensive crisis:

Systolic over 180 and/or diastolic over120, with patients needing prompt changes in medication if there are no other indications of problems, or immediate hospitalization if there are signs of damage.

DCCT and UKPDS: With BP control both DR and related nephropathy are reduced

DR Care Process: Systemic Risks

Cholesterol targets in Adults with Diabetes LDL cholesterol <100 mg/dl (2.60 mmol/l) HDL cholesterol >40 mg/dl (1.02 mmol/l) In women, who tend to have higher HDL cholesterol Levels than men, HDL goal 10 mg/dl higher Triglyceride levels are <150 mg/dl (1.7 mmol/l)

Control of Cholesterol will help reduce both system CVD risks of heart attacks and strokes and also **diabetic edema**

Aspirin Aspirin does not slow progression of DR Aspirin (for CVD TX) does not make DR worse

DR Care Process: Evaluation

1. Comprehensive Exam

- 1. If IOP is elevated with screening devices
 - 1. Goldman if still high
 - 2. Gonio Exam

2. Undilated exam not that useful Unless paired with widefield imaging does have a role Very Good Screening tool Good Treatment Tool

4. OCT (ideally Spectral Domain or Swept Source)

- 4. If Va is 20/20 likely not standard of care/required
- 5. If Va is less than 20/20 (even 20/25) OCT should be done.
- 5. Angiography (FA and OCTA)
 - 4. When is the ideal time to do is the most important question

DR Care Process: Evaluation Treatment Indications for VTDR Severe NPDR **Diabetic Macular Edema** PDR Retina detachment related to DR Glaucoma related to DR


DR Care Process: Treatment Treatment options for VTDR Medical Therapy Intraocular antiVEGF TX Intraocular steroid TX Surgical Therapy Ocular Laser **Ocular Surgery (Vitrectomy)**

Treatment options for VTDR Medical > Surgical **Diabetic Macular Edema** Intraocular anti-VEGF TX Intraocular steroid TX Surgical mixed in with Medical supported by new studies Severe NPDR PDR Glaucoma related to PDR Surgical > Medical Retina detachment related to DR Glaucoma related to PDR Ocular Laser Ocular Surgery (Vitrectomy)

Laser Treatment:


Pan retinal Photocoagulation or focal

Green, Red, Yellow Single shot Multiple shot Computer Guided











Medical Treatment: Intravitreal Injections AntiVEGFs: Avastin,Lucentis, Eylea Steroids: Injection: Preservative free Kenolog Implants: Dexamethosone, Fluocinolone



Vitrectomy 20, 23, 25, 27 Gauges





DR Care Process: Informed Medical Team

Reinforce with patients our combined efforts & Communicate with each other


Diabetic Control, Hypertension, Weight, Cholesterol

Determine Severity of Retinopathy

Frequency of follow-up Normal or mild = yearly Moderate = 6 months Severe or advanced = treatment and close follow up Treatment recommendations Minimize retinal edema Minimize abnormal new blood vessels Minimize Vitreous hemorrhage or tractional retinal detachment

DR Care Process: Follow-up Normal or mild NPDR no macular edema Yearly follow-up Mild NPDR with macular edema 4-6 month follow-up Moderate NPDR with or without macular edema 4-6 month follow-up Severe NPDR with or without macular edema 2-4 month follow-up without treatment Close follow-up during treatment **Proliferative Retinopathy PDR (+/-Glaucoma or TRD)** Close follow-up during treatment Close follow-up means 1 month or less

- A 50 year old Hispanic male notes a gradual decrease in vision in both eyes over several months.
- His medical history includes 20 years of DM of which 15 years with insulin for "control" but in all 20 years his blood sugar control has been ok. He remembers an eye exam for glasses about 2 years ago. At this exam: Visual acuity in 20/200 OU both eyes. Blood pressure in 150/95, Recent HbA1C is 9.5, Dilated exam of his left eye shows:



Q1:

This fundus picture best represents what type of diabetic retinopathy?

- A. Mild, Non-Proliferative diabetic retinopathy
- B. Moderate, Non-Proliferative diabetic retinopathy
- C. Proliferative diabetic retinopathy with presence of extensive neovascularization of the disc
- D. Proliferative diabetic retinopathy with presence of tractional retinal detachment

C. High Risk, Proliferative diabetic retinopathy with presence of extensive neovascularization of the disc

Q2:

Which of the following pairs in this patient's history are the most important **RISK FACTORS** to the development of severe diabetic retinopathy?

- A. Length of History of diabetes in years and hypertension
- B. Level of high blood sugars and high cholesterol
- C. Length of history of diabetes in years <u>and</u> level of high blood sugars
- D. Duration of obesity and level of high blood sugars

C. Length of history of diabetes in years <u>and</u> level of high blood sugars

Q3:

- Which of the following paired eye exam findings to potential treatment (s) is most correct for this patient?
- A. Proliferative diabetic retinopathy <u>and prompt</u> (in 1 wk) pan-retinal laser with or without injection of anti-VEGF
- B. Vitreous Hemorrhage <u>and</u> urgent (in 24-48 hours) vitrectomy surgery with or without injection of anti-VEGF
- C. Clinical Suspicion of orbital Mucor in patient with DKA <u>and</u> routine outpatient ENT referral
- D. Clinical Diagnosis of visual insignificant diabetic related cataract <u>and</u> routine (6 month) referral for evaluation for cataract surgery
- A. Proliferative diabetic retinopathy <u>and prompt</u> (in 1 wk) panretinal laser with or without injection of anti-VEGF

Questions?





